Johnson & Johnson Commemorates 50 Years in Singapore With a Series of Events Marking a Remarkable Milestone
BeiGene Initiated at Outperform at JMP Securities on Strength of Brukinsa
Citi Maintains Johnson & Johnson(JNJ.US) With Buy Rating
Citi analyst Joanne Wuensch maintains $Johnson & Johnson(JNJ.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 63.8% and a total average return of 6.4% over the
Johnson & Johnson (JNJ) Faces Legal Challenges While Advancing MedTech Innovations for Growth
U.S. To J&J: Don't Target Hospital Drug Discounts -- WSJ
Sector Update: Health Care Stocks Steady Premarket Tuesday
Sector Update: Health Care
A judge in Oregon overturned the verdict of the Johnson & Johnson talcum powder case and ordered a retrial.
On September 17th, according to Reuters, a judge in Oregon overturned a jury's decision to award $0.26 billion in compensation to Johnson & Johnson. The plaintiff in the lawsuit claimed to have developed mesothelioma, a fatal cancer related to asbestos exposure, from inhaling the company's talcum powder. According to a spokesperson for Johnson & Johnson, Judge Katharine von ter Stegge in Portland approved the company's motion to overturn the verdict and ordered a new trial. Written opinions are expected to be released in the next few days. The Vice President of Global Litigation at Johnson & Johnson is responsible for the litigation.
This Johnson & Johnson Insider Reduced Their Stake By 37%
CG Oncology Surges 7%; Seen Benefitting From J&J Bladder Cancer Asset Data
Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target
Johnson & Johnson Analyst Ratings
Johnson & Johnson Says Its Bladder Cancer Drug Combined With Cetrelimab Shows High Response Rate in Study
Express News | J&J - Shockwave Medical, Announced Full U.S. Launch of Shockwave E8 Peripheral Ivl Catheter
Reported Saturday, Johnson & Johnson Shares New Data on RYBREVANT in Metastatic Colorectal Cancer at ESMO Congress
Express News | J&J: Tar-200 Plus Cetrelimab Effective in Reducing Tumor Size in Those With Muscle-Invasive Disease
Do Queasy Side Effects Mean the End of Weight-loss Drug Stock Hype?
Express News | J&J-New Data From Tar-200 Phase 2B Sunrise-1 Study Show 84% Complete Response Rate in Patients With High-Risk Non-Muscle-Invasive Bladder Cancer
J&J Leads H1 Healthcare Deals as Big Pharma Dealmaking Returns: Report
Express News | Rybrevant® (Amivantamab-Vmjw) Plus Chemotherapy Shows Positive Overall Survival Trend Versus Chemotherapy in Patients With Previously Treated Egfr-Mutated Lung Cancer